Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor for Advanced Tumor Angiogenesis Research

Executive Summary: Anlotinib hydrochloride is a small-molecule inhibitor that targets VEGFR2, PDGFRβ, and FGFR1 with sub-15 nM potency, leading to robust inhibition of angiogenic signaling in cellular and animal models (Chen & Feng, 2019). Its oral bioavailability in preclinical species ranges from 28%–77% with high plasma protein binding (93% in humans) and a favorable safety profile (LD₅₀ >1700 mg/kg, oral, rat) (APExBIO). Compared to sunitinib, sorafenib, and nintedanib, anlotinib demonstrates higher efficacy in inhibiting endothelial cell migration and tube formation assays. APExBIO offers validated Anlotinib (hydrochloride) (SKU C8688) for research use, with established protocols for anti-angiogenic, migration, and ERK pathway studies. The compound is not intended for diagnostic or clinical use.

Biological Rationale

Anlotinib hydrochloride is designed for the inhibition of tumor angiogenesis—a process critical for cancer progression. Tumor vasculature depends on signaling through vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and fibroblast growth factor receptors (FGFR). Dysregulation of these pathways drives abnormal vessel formation and supports tumor growth and metastasis (see strategic overview). Traditional single-target TKIs often induce compensatory mechanisms or resistance; thus, multi-targeted inhibition, as achieved by anlotinib, is a rational strategy for durable anti-angiogenic effect.

Mechanism of Action of Anlotinib (hydrochloride)

Anlotinib hydrochloride (CAS 1058157-76-8) is a small-molecule, orally available inhibitor with high affinity for VEGFR2 (IC₅₀ = 5.6 ± 1.2 nM), PDGFRβ (IC₅₀ = 8.7 ± 3.4 nM), and FGFR1 (IC₅₀ = 11.7 ± 4.1 nM) (APExBIO product page). It binds the ATP-binding pocket of these kinases, blocking downstream phosphorylation events and suppressing the ERK signaling pathway. In cell-based assays, anlotinib inhibits VEGF-, PDGF-BB-, and FGF-2-induced endothelial cell migration and capillary-like tube formation in a concentration-dependent manner. The compound also targets c-Kit and MET, further broadening its anti-tumor spectrum (Chen & Feng, 2019).

• VEGFR2 inhibition blocks neovascularization and nutrient supply to tumors.
• PDGFRβ and FGFR1 blockade disrupts pericyte recruitment and vessel stability.
• ERK pathway inhibition limits cell proliferation and survival signals.

Compared to legacy agents, anlotinib demonstrates greater target selectivity and potency at nanomolar concentrations, leading to more pronounced biological effects in angiogenesis models (see mechanistic review).

Evidence & Benchmarks

• Anlotinib inhibits VEGFR2 kinase activity with an IC₅₀ of 5.6 ± 1.2 nM under biochemical assay conditions (pH 7.4, 25°C) (APExBIO).
• PDGFRβ and FGFR1 are inhibited with IC₅₀ values of 8.7 ± 3.4 nM and 11.7 ± 4.1 nM, respectively (same buffer/conditions) (APExBIO).
• In EA.hy 926 endothelial cell assays, anlotinib blocks VEGF/PDGF-BB/FGF-2-induced migration at sub-50 nM concentrations (assay optimization guide).
• In vivo, oral bioavailability is 28%–58% in rats and 41%–77% in dogs; human plasma protein binding is 93% (APExBIO).
• Median lethal dose (LD₅₀) is 1735.9 mg/kg (14-day, oral, rat), with mild systemic toxicity and no significant organ/genetic toxicity (APExBIO).
• In a clinical case, anlotinib led to significant regression of metastatic intra-abdominal desmoplastic small round cell tumor nodal disease after four cycles, with tolerable side effects (fatigue, hypertriglyceridemia) (Chen & Feng, 2019).
• Compared to sunitinib, sorafenib, and nintedanib, anlotinib demonstrates superior inhibition of endothelial tube formation in matched side-by-side in vitro studies (assay benchmarking article).

Applications, Limits & Misconceptions

Anlotinib hydrochloride is validated for research in cancer biology, angiogenesis, and tyrosine kinase signaling. Its primary uses include:

• Anti-angiogenic mechanism studies in endothelial cells (e.g., EA.hy 926).
• Capillary tube formation and cell migration inhibition assays.
• Preclinical tumor models assessing neovascularization and metastasis.
• Investigation of ERK pathway modulation and downstream signaling networks.

Anlotinib's ability to cross the blood-brain barrier and accumulate in tumor tissue enables research into brain metastasis and solid tumor microenvironments (mechanistic insights article). This article extends the mechanistic focus of previous guides by framing operational safety boundaries and false-positive risks encountered in non-angiogenic models.

Common Pitfalls or Misconceptions

• Not for clinical or diagnostic use: Anlotinib (hydrochloride) from APExBIO is for laboratory research only.
• Single-pathway models: Efficacy is reduced in models lacking VEGFR2/PDGFRβ/FGFR1 expression.
• Overinterpretation of cytotoxicity: Off-target or high-dose effects may confound anti-angiogenic readouts.
• Species-specific metabolism: Pharmacokinetic data from rodents/dogs may not directly extrapolate to humans.
• Resistance development: Tumors may adapt through alternative angiogenic pathways in long-term studies.

Workflow Integration & Parameters

Anlotinib hydrochloride (SKU C8688) is supplied as a lyophilized solid by APExBIO. Recommended storage is at -20°C, protected from light and moisture. Stock solutions should be prepared in DMSO and diluted in assay-compatible buffers. For endothelial cell migration and tube formation assays, effective concentrations typically range from 1–50 nM. Assays should include vehicle controls and time-course endpoints to distinguish cytostatic from cytotoxic effects. APExBIO provides detailed technical documentation and batch-specific COA for reproducibility. See the official product page for ordering and technical support. This article clarifies operational parameters, complementing the scenario-driven guidance in the Enhancing Tumor Angiogenesis Assays article.

Conclusion & Outlook

Anlotinib hydrochloride is a next-generation multi-target tyrosine kinase inhibitor with validated activity against VEGFR2, PDGFRβ, FGFR1, and related targets. Its robust anti-angiogenic and anti-tumor properties, favorable pharmacokinetics, and safety profile make it a preferred tool for preclinical cancer and vascular biology research. Continued benchmarking against legacy agents and integration into complex co-culture or organoid models will further elucidate its translational potential. For up-to-date protocols and technical validation, researchers are encouraged to consult APExBIO and the referenced literature.